The RATIO: Registry of Infections and Lymphoma in Patients Treated With TNF-a Antagonists
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00224562 |
Recruitment Status : Unknown
Verified February 2004 by Assistance Publique - Hôpitaux de Paris.
Recruitment status was: Recruiting
First Posted : September 23, 2005
Last Update Posted : October 26, 2005
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Rheumatoid Arthritis Crohn's Disease Ankylosing Spondylitis Psoriasis | Drug: TNF-alpha antagonists |
Study Type : | Observational |
Observational Model: | Case-Control |
Time Perspective: | Prospective |
Official Title: | The RATIO Registry: French Registry on Opportunistic and Severe Bacterial Infections and Lymphoma in Patients Treated With TNF-a Antagonists |
Study Start Date : | February 2004 |

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | Child, Adult, Older Adult |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria for cases:
- past or current treatement with TNF-a antagonists
- either lymphoma severe bacterial infection opportunistic infection
Inclusion Criteria for controls:
- matched with cases by gender, age (+/- 5 years), underlying disease (rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, or psoriasis)
- past or current treatement with TNF-a antagonists
- no lymphoma, severe bacterial infection, opportunistic infection (same as case)
Exclusion Criteria:
- none

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00224562
Contact: Florence TUBACH, MD | 01 40 25 62 51 | florence.tubach@bch.aphp.fr |
France | |
All French departments of rheumatology, internal medicine, gastro-enterology, dermatology, infectious diseases, intensive care unit, oncology and haematology, paediatrics and chest medicine | Recruiting |
All Cities, France | |
Contact: Florence Tubach, MD 01 40 25 62 51 florence.tubach@bch.aphp.fr |
Principal Investigator: | Xavier Mariette, MD PhD | Assistance Publique - Hôpitaux de Paris | |
Principal Investigator: | Dominique Salmon, MD | Assistance Publique - Hôpitaux de Paris | |
Principal Investigator: | Marc Lemann, MD | Assistance Publique - Hôpitaux de Paris |
ClinicalTrials.gov Identifier: | NCT00224562 |
Other Study ID Numbers: |
1 INSERM |
First Posted: | September 23, 2005 Key Record Dates |
Last Update Posted: | October 26, 2005 |
Last Verified: | February 2004 |
TNF alpha antagonists infections lymphoma safety |
Infection Spondylitis Lymphoma Spondylitis, Ankylosing Crohn Disease Psoriasis Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases Arthritis Joint Diseases |
Musculoskeletal Diseases Skin Diseases, Papulosquamous Skin Diseases Inflammatory Bowel Diseases Gastroenteritis Gastrointestinal Diseases Digestive System Diseases Intestinal Diseases Bone Diseases, Infectious Bone Diseases Spinal Diseases Spondylarthropathies Spondylarthritis Ankylosis |